The global abdominal aortic aneurysm (AAA) treatment market is projected to reach USD 2,305.8 million 2025, growing at a CAGR of 5.3%, reaching USD 3,864.7 million by 2035. This is largely attributed to the increased incidence of AAA, especially in the elderly population, as well as an increased compliance for minimally invasive procedures (such as endovascular aneurysm repair [EVAR]). Rise of imaging and surgical technologies as well as increased awareness of early diagnosis among population is a catalysing cause for this market.
Some of the important factors driving the growth of this market are advancement in medical technologies, increasing healthcare infrastructure, and rising government initiatives for improving the quality of cardiovascular health. Abdominal aortic aneurysm (AAA) is one of the most common types of vascular disease around the world and its incidence is increasing due to the increased prevalence of life style-related risk factors including smoking, hypertension, and obesity, which indicate that there is an increasing need for effective therapy.
Market Metrics
| Metric | Value |
|---|---|
| Market Size (2025E) | USD 2,305.8 million |
| Market Value (2035F) | USD 3,864.7 million |
| CAGR (2025 to 2035) | 5.3% |
North America is likely to capture a significant proportion of the AAA treatment market due to continuous expenditure in the healthcare sector, developed healthcare infrastructure, and increasing geriatric population. Due to the increasing incidence of cardiovascular diseases, coupled with the availability of advanced surgical methods such as EVAR and open surgery, North America is expected to dominate the market. It is also because this region is home to a growing number of skilled professionals and a high volume of health-related procedures (particularly biopsy) performed in this region.
Awareness of AAA among health-care professionals and patients is presenting more of an opportunity for growth in the European market, as the AAA therapies have started to gain a stronghold there, too. For instance, growing aged population in the nations like Germany, and France are predicted to boost the growth of abdominal aortic aneurysm (AAA) management market.
Also, the growth of the market in the region will be supported by a well-informed healthcare system and a high acceptance of advanced treatment options like endografts for EVAR. Also, the availability of key market players and ongoing researches in the field of AAA therapeutics technologies fuels the market in the region.
The AAA treatment market is expected to grow fastest in the Asia-Pacific region till 2035. Such growth is attributed to the growing incidence of cardiovascular diseases, the increasing geriatric population and the growing availability of awareness on AAA in emerging nations including China, India, and Japan.
Improving healthcare infrastructure and growing affordability of advanced medical treatments in this region are aiding to increase the adoption of traditional and minimally invasive AAA treatment methods in this region. The rising healthcare expenditure in emerging markets is also contributing to the demand for AAA treatments.
Challenge
High Treatment Costs and Limited Access
One of the significant challenges in the AAA treatment market is the high cost of treatments, especially advanced procedures like endovascular aneurysm repair (EVAR). The cost of these treatments makes them often unaffordable in developing areas with smaller healthcare budgets. Patients with AAA tend to wait until the rupture occurs to seek treatment, making treatment options difficult and contributing to high health resource consumption.
Opportunity
Advancements in Minimally Invasive Procedures
The rising preference for minimally invasive surgical techniques like EVAR is opening up new avenues for market expansion. This results in shorter recovery periods, lower rates of complications, and lower hospital stays, all of which make these procedures increasingly appealing to both patients and healthcare providers. Interventional cardiology more advanced endografts and stent grafts expected to improve AAA outcomes will further boost the AAA treatment procedures demand.
The AAA treatment market was gradually growing during the period 2020 to 2024 due to the increasing incidence of cardiovascular diseases and the rising preference for minimally invasive treatment. The use of fewer invasive endovascular techniques (EVAR), which offer lower risk and decreased recovery times than traditional open surgical techniques led to the rise in these procedures. Throughout this time, the progression of stent graft technology and endografts was instrumental in the growing success of AAA treatment.
From 2025 to 2035, the market will likely see a major evolution, with increases in the prevalence of minimally invasive procedures and the emergence of next-generation endovascular products. New materials and technologies should make treatments more effective and affordable. The future of AAA treatment encompasses advancements in endovascular techniques, biomaterials, gene therapy, and patient monitoring, with the potential for significantly improved patient outcomes through minimally invasive procedures, personalized approaches, and timely interventions.
Market Shifts: A Comparative Analysis 2020 to 2024 vs. 2025 to 2035
| Market Shift | 2020 to 2024 |
|---|---|
| Treatment Methods | Focus on traditional open surgery and early adoption of EVAR. |
| Regulatory Environment | Moderate regulatory advancements in the use of endovascular devices. |
| Technological Integration | Introduction of improved stent grafts and imaging technologies. |
| Market Expansion | Growth in developed regions with high healthcare infrastructure. |
| Consumer Preferences | Focus on patient awareness and early diagnosis. |
| Market Shift | 2025 to 2035 |
|---|---|
| Treatment Methods | Increased use of EVAR and continued development of minimally invasive approaches. |
| Regulatory Environment | Stringent regulations on device safety and efficacy, encouraging innovation. |
| Technological Integration | Development of personalized endografts and the use of 3D printing for tailored treatments. |
| Market Expansion | Expansion into emerging markets due to improved healthcare access and awareness. |
| Consumer Preferences | Growing demand for minimally invasive procedures and personalized treatment options. |
The increasing incidence of AAA has been attributed to the rising risk factors of atherosclerosis, smoking, and hypertension. Increasing number of new endovascular aneurysm repair (EVAR) procedures and ageing population are some major driving factors for the market growth.
Minimal invasive surgical procedures and development of stent grafts are further driving treatment & post-operative recovery rate which is expected to drive the adoption rate of AAA treatments over the forecast period. The USA medical device market contributes significantly to the overall market growth, with many leading medical device producing companies operating in this region, which result in high availability of advanced treatment options.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 5.5% |
The UK AAA treatment market is expected to increase at a CAGR of 5.0% during the forecast period. Increasing awareness regarding AAA and improved diagnostic techniques such as ultrasound and CT scans are supporting early diagnosis and treatment. Growing preference for less invasive treatments such as EVAR is expected to drive the market growth.
Another crucial factor fuelling the growth of the UK AAA market is the ageing population in the country which is also a major driver for increasing the number of AAA cases and thus boosting the market for AAA intervention.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 5.0% |
European Union AAA therapeutics market is anticipated to grow at a 5.3% CAGR. The rising geriatric population and the rising prevalence of risk factors such as smoking and obesity are the major factor driving the growth of the market. Several European countries (Germany, France, and Italy), have reported a rise in AAA cases and subsequently the need for surgical and endovascular repairs.
Technological errors have also been contributing to the market as stent grafts are providing improved outcomes and reduced recovery durations for patients. The growing acceptance of personalized therapy and advancements in post-operative management are anticipated to advance the treatment paradigm at the regional level.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 5.3% |
Japan
Japan AAA treatment market is expected to grow at a CAGR of 5.1% during the forecast period. The fast-aging population of Japan has also contributed to the increasing occurrence of AAA in this country. Demand for endovascular treatments is stimulating the market, due to established techniques such as EVAR, propelled by their minimal invasiveness. Growing awareness among the patients as well as healthcare professionals about the risk factors for AAA is promoting early diagnosis and constant treatment, thereby aiding the growth of the market.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 5.1% |
AAA is the abdominal aortic aneurysm South Korea AAA treatment market is expected to grow at a compound annual growth rate (CAGR) of 5.2%. South Korea’s modern healthcare system has developed rapidly in recent decades and has made AAA diagnosis and management increasingly more effective.
Increasing uptake of minimally invasive surgical techniques is fuelling market growth as they can leap to a speedier recovery from lower complication rates. Rising awareness about AAA and the growing availability of the sophisticated stent grafts are anticipated to further contribute towards the market growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 5.2% |
| By Treatment Type | Market Share (2025) |
|---|---|
| Endovascular Aneurysm | 44.5% |
The 2025 preferred AAA treatment market is dominated in terms of the share that endovascular aneurysm repair (EVAR) occupied with 44.5%. This niche is accepted because it has less intervention, easy operation risk and also faster recovery period post operation than an open surgery. The world population continues to age, and with the aging population, the prevalence of aortic aneurysms is increasing. This trend will enhance the need for less invasive procedures.
The stent graft is delivered with less invasion compared to open techniques that necessitate larger abdominal incisions an EVAR-procedure enters through small incisions in the groin and directs the stent graft to the aneurysm through imaging technology. This reduces the duration of hospitalization, the chances of post-operative complications and the recovery period. The need for EVAR has been compounded by improvements in device design (branch and fenestrated stent grafts) capable of treating more complex anatomies.
Among the high-risk patients who may not withstand open surgery, especially patients with comorbidities such as hypertension and chronic kidney disease, physicians are increasingly choosing EVAR. This combined with rapid development of imaging and navigation system make the procedure more accuracy and safety, thus become the most common treatment choice.
| By End User | Market Share (2025) |
|---|---|
| Hospitals | 69.8% |
Some hospital-based multidisciplinary teams incorporate specialists like vascular surgeons, interventional radiologists, and anaesthesiologists to provide comprehensive preoperative evaluation and postoperative care. Such collaboration is vital in this high-risk AAA patient group where there can be significant complications without immediate coordinated team response.
Large tertiary care hospitals are usually equipped for the emergent surgical management of an AAA rupture, albeit they require timely diagnosis and prompt surgical care. An increase in the number of vascular surgery centres in hospitals combined with growing acceptance for reimbursement of endovascular procedures will fuel the market.
The other half of hospitals is they are the lifeblood of the trial world, they are the heart of God’s universe where grafts are invented and new therapies are acquiesced. North America and Europe will be the highest procedural markets in the world, and therefore hospitals will hold most of the treatment market for the AAA.
The latest minimally invasive techniques in abdominal aortic aneurysms surgery, along with a constant focus on cardiovascular diseases and developments in diagnostic imaging and surgical devices are driving the abdominal aortic aneurysm (AAA) treatment market towards an advancement. The goal is improved patient outcome by more minimally invasive options certain to be at least endovascular aneurysm repair EVAR and improvements in devices such as stent grafts.
Traditionally, a more extensive open surgical approach has been employed, but with the development of endovascular techniques, the open approach has been left behind due to advantages of shorter recovery times, lower complication rates, and improved long-term outcomes. Along with these therapies, several novel drug-based therapies and biomarkers in the pipeline are in clinical studies for preventing aneurysm rupture and delaying aneurysm progression.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Medtronic plc | 25-30% |
| Johnson & Johnson | 18-22% |
| Cook Medical | 12-16% |
| Endologix, Inc. | 10-14% |
| Terumo Corporation | 8-12% |
| Other Companies (combined) | 18-23% |
| Company Name | Key Offerings/Activities |
|---|---|
| Medtronic plc | In 2024, Medtronic expanded its stent graft offerings with the launch of the Endurant II, featuring improved sealing technology for better durability. |
| Johnson & Johnson | Launched the Nellix EndoVascular Aneurysm Sealing System in 2024, focusing on sealing technology and improved patient outcomes through a fully integrated system. |
| Cook Medical | Continued expansion of the Zenith Stent Graft family, focusing on customization for complex anatomies in 2024 and launched a new low-profile device in 2025. |
| Endologix, Inc. | In 2024, Endologix advanced its AFX Endovascular Stent Graft system with innovations in patient-specific fitting and reduction of leakage rates. |
| Terumo Corporation | Focused on developing next-generation vascular access devices to support EVAR procedures, with new technological features aimed at improving clinical outcomes in 2025. |
Key Company Insights
Medtronic plc (25-30%)
Medtronic is the market leader in the AAA treatment space, particularly with its Endurant stent grafts. The company continues to expand its portfolio through technological advancements, including stent grafts with enhanced sealing mechanisms and longer durability.
Johnson & Johnson (18-22%)
Johnson & Johnson's focus on biologically integrated devices, such as the Nellix system, provides a comprehensive solution for AAA treatment. The company is leading efforts in addressing endograft complications through its sealing system and integrated patient management tools.
Cook Medical (12-16%)
Cook Medical's Zenith line of stent grafts remains a popular choice for both primary and complex AAA cases. The company’s focus on personalized treatment options and continuous improvements in device profiles positions it as a key player in the market.
Endologix, Inc. (10-14%)
Endologix has carved out a strong position with its AFX Endovascular Stent Graft system. The company focuses on reducing complications like endoleaks and device migration, and its next-generation offerings are expected to solidify its market share.
Terumo Corporation (8-12%)
Terumo is growing its presence in the AAA treatment space, particularly in markets that are adopting minimally invasive procedures. Their focus on improving delivery systems for EVAR procedures is key to their ongoing product developments.
Other Key Players (18-23% Combined)
The market size of the abdominal aortic aneurysm treatment market in 2025 was USD 2,305.8 million.
The abdominal aortic aneurysm treatment market is projected to reach USD 3,864.7 million by 2035.
Key growth drivers include increasing prevalence of vascular disorders, advancements in minimally invasive surgical techniques, and rising awareness for early detection of aneurysms.
The top contributors are USA, UK, European Union, Japan and South Korea.
The endovascular aneurysm repair (EVAR) segment is anticipated to dominate due to its reduced recovery time and growing adoption in both elective.
Explore Therapy Area Insights
Abdominal Aortic Aneurysm Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
